Media Contact
+886-2-2627-2707AltruBio to present at Biotech Showcase Digital 2021.
AltruBio pioneers the development of a number of agonist antibodies targeting the PSGL-1 immune checkpoint regulator. Its lead molecule, Neihulizumab has now demonstrated clinical results in sr-aGVHD, Ulcerative Colitis, Psoriasis, and Psoriatic Arthritis.
AltruBio Announces First Patient Dosed in Phase 1b Study of Neihulizumab in Patients with Steroid-Refractory Acute Graft-versus-Host Disease.
AltruBio Inc. moves forward with clinical development of Neihulizumab in Steroid-Refractory Acute Graft-versus-Host Disease after encouraging Phase 1a results
AltruBio Inc. presented AbGn-107 Phase 1a chemo-refractory GI cancer results at ASCO-GI 2020
AltruBio’s presentation on Neihulizumab Phase 2a Ulcerative colitis results selected as Poster of Distinction at Digestive Disease Week (DDW) 2020
AltruBio
top